Robert LeBoyer

Stock Analyst at Noble Capital Markets

(1.18)
# 3,645
Out of 5,182 analysts
18
Total ratings
31.25%
Success rate
-0.26%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $12.71
Upside: +450.75%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $3.76
Upside: +245.74%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150$250
Current: $1.10
Upside: +22,627.27%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $7.17
Upside: +736.82%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $5.33
Upside: +1,025.70%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.48
Upside: +187.36%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.25
Upside: +1,020.00%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.56
Upside: +412.82%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $3,000
Current: $5.95
Upside: +50,320.17%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.17
Upside: -
Initiates: Buy
Price Target: $12
Current: $3.37
Upside: +256.08%
Initiates: Buy
Price Target: $9,900,000
Current: $2.26
Upside: +437,143,892.58%
Downgrades: Neutral
Price Target: n/a
Current: $31.97
Upside: -
Initiates: Buy
Price Target: $15
Current: $2.55
Upside: +488.24%